Chargement en cours...
Neurological safety of fingolimod: An updated review
Fingolimod (FTY) is the first oral medication approved for treatment of relapsing–remitting multiple sclerosis (RRMS). Its effectiveness and safety were confirmed in several phase III clinical trials, but proper evaluation of safety in the real patient population requires long‐term post‐marketing mo...
Enregistré dans:
| Publié dans: | Clin Exp Neuroimmunol |
|---|---|
| Auteurs principaux: | , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
John Wiley and Sons Inc.
2017
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5575715/ https://ncbi.nlm.nih.gov/pubmed/28932291 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cen3.12397 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|